EC Number   |
General Information |
Reference |
|---|
   3.4.22.15 | evolution |
cathepsin L is a member of the cysteine cathepsin protease family |
752936 |
| 3.4.22.15 | evolution |
cathepsin L-like protease is an important member of the papain-like cysteine protease and plays numerous indispensable roles in the biology of parasitic organisms |
754985 |
| 3.4.22.15 | evolution |
phylogenetic analysis reveals that SoCatL is evolutionally close to fish cathepsin L, especially those belonging to the Perciformes order. The enzyme possesses the typical cathepsin L-like domain architecture, i.e. a signal peptide (residues 1-19), an N-terminal proregion classified as protease inhibitor I-29 (residues 27-87) and a C-terminal C1-peptidase domain (residues 119-334) |
753596 |
| 3.4.22.15 | evolution |
the enzyme sequence comtains conserved ERFNIN, GNYD, and GCGG motifs, which are characteristics of cathepsin L |
753600 |
| 3.4.22.15 | malfunction |
ablation of cathepsin L in a cystatin M/E-deficient background (Cst6-/-Ctsl-/-double-knockout mice) restores viability and results in normalization of stratum corneum morphology |
711963 |
| 3.4.22.15 | malfunction |
cathepsin L knockout mouse brains show extensive decreases in dynorphin A, dynorphin B, and alpha-neoendorphin that are reduced by 75%, 83%, and 90%, respectively |
713022 |
| 3.4.22.15 | malfunction |
cathepsin L pharmacological inhibition significantly attenuates lysosomal membrane permeabilization, mitochondrial membrane permeabilization, and apoptosis |
711640 |
| 3.4.22.15 | malfunction |
deficiency for cathepsin L promotes enhanced tumor progression and metastasis in mouse epidermis, Ctsl deficiency potentiates neoplastic progression in K14-HPV16 transgenic mice but does not alter immune cell infiltration or angiogenesis during neoplastic progression in HPV16 mice |
713155 |
| 3.4.22.15 | malfunction |
in cathepsin L knockou mice, brain levels of (Met)enkephalin are reduced to 44%, brain levels of neuropeptide Y are reduced to 22%, brain levels of cholecystokinin are reduced to 75%, brain levels of dynorphin A are reduced to 25% , brain levels of dynorphin B are reduced to 17%, brain levels of alpha-neoendorphin are reduced to 10%, brain levels of adrenocorticotropin hormone are reduced to 23%, brain levels of beta-endorphin are reduced to 18%, and brain levels of alpha-MSH are reduced to 7% of the wild type level |
717285 |
| 3.4.22.15 | malfunction |
in cathepsin L knockout mice, cholecystokinin 8 levels are substantially reduced in brain cortex by an average of 75% |
713190 |
